Anemia, the reduction of functional red blood cells (RBCs) or hemoglobin (Hb) below the physiologic norm, is one of the most common hematologic abnormalities seen in veterinary practice. While a mild decrease in packed cell volume (PCV) may be incidental, moderate‑to‑severe anemia can be life‑threatening, reflecting underlying blood loss, bone‑marrow failure, or premature RBC destruction.
In dogs, anemia is a clinical sign rather than a disease; it is the downstream result of a diverse group of pathophysiologic mechanisms. Understanding these mechanisms, recognizing the subtle (and sometimes overt) clinical clues, and applying a systematic diagnostic approach are essential for timely, effective treatment and for improving long‑term outcomes.
This guide consolidates the latest peer‑reviewed literature, board‑certified veterinary textbooks, and clinical guidelines (e.g., ACVIM, AAHA) into a single, organized resource that veterinarians, veterinary technicians, and informed pet owners can reference.
2. What Is Anemia?
| Parameter | Normal Range (Adult Dogs) | Clinical Definition of Anemia* |
|---|---|---|
| Packed Cell Volume (PCV) / Hematocrit (HCT) | 38 %–55 % (≈ 45 % ± 5 %) | PCV < 35 % (mild), 20–35 % (moderate), < 20 % (severe) |
| Hemoglobin (Hb) | 12–18 g/dL | Hb < 11 g/dL (mild), 8–11 g/dL (moderate), < 8 g/dL (severe) |
| Red Blood Cell Count (RBC) | 5.5–8.5 × 10⁶/µL | RBC < 5.0 × 10⁶/µL (mild), 3.0–5.0 × 10⁶/µL (moderate), < 3.0 × 10⁶/µL (severe) |
*Thresholds may vary slightly between laboratories and according to the dog’s breed, age, and physiological status (e.g., pregnancy).
Functional anemia occurs when RBCs are present in normal numbers but are unable to transport oxygen effectively (e.g., due to abnormal hemoglobin or severe hypoxia). This guide focuses on quantitative anemia (decreased RBC mass), which is far more prevalent in canine patients.
3. Pathophysiologic Categories & Common Causes
Anemia in dogs is broadly grouped into four mechanistic categories, each with a set of primary and secondary etiologies.
| Category | Mechanism | Representative Causes |
|---|---|---|
| Hemorrhagic (Blood‑Loss) Anemia | Acute or chronic loss of whole blood or plasma. | • Traumatic wounds, gunshot, bite wounds • Gastrointestinal (GI) ulceration, neoplasia, parasites (e.g., Ancylostoma, Trichuris) • Coagulopathies (e.g., hemophilia A/B, von Willebrand disease, rodenticide toxicity) • Post‑operative bleeding, splenic rupture |
| Hemolytic Anemia | Premature destruction of RBCs (intravascular or extravascular). | • Immune‑mediated hemolytic anemia (IMHA) – primary (idiopathic) or secondary (infection, drug‑induced) • Infectious agents: Ehrlichia canis, Babesia canis, Mycoplasma haemocanis • Toxins: zinc, copper, lead, certain snake venoms • Inherited defects: hereditary spherocytosis, pyruvate kinase deficiency, glucose‑6‑phosphate dehydrogenase (G6PD) deficiency |
| Aplastic (Bone‑Marrow Failure) Anemia | Decreased production of RBCs (often pancytopenia). | • Myelotoxic drugs (e.g., chemotherapy, chloramphenicol, sulfonamides) • Viral infections (e.g., parvovirus in puppies, canine distemper) • Immune‑mediated aplastic anemia • Chronic inflammatory disease (anemia of chronic disease) • Nutritional deficiencies (iron, copper, B‑vitamins) |
| Dilutional (Regenerative) Anemia | Apparent anemia due to plasma volume expansion, not true loss of RBCs. | • Aggressive fluid therapy • Over‑hydration in critical care (rarely clinically significant) |
Key Concept: The regenerative response (elevated reticulocyte count) helps differentiate hemolytic or hemorrhagic anemia (usually regenerative) from aplastic or chronic disease anemia (non‑regenerative).
4. Clinical Signs & Symptoms
The clinical picture of anemia is often subtle until the PCV drops below ~30 %. Signs are primarily related to tissue hypoxia and compensatory cardiovascular responses.
| System | Common Findings | Clinical Pearls |
|---|---|---|
| General | Lethargy, weakness, exercise intolerance, decreased appetite, weight loss | Dogs may “hold up” during walks; owners notice slower pacing. |
| Mucosal Membranes | Pale or grayish gums, conjunctiva, oral mucosa; prolonged capillary refill time (CRT > 2 s) | Compare to a healthy dog’s pink, moist gums; blanching after gentle pressure is a quick bedside test. |
| Cardiovascular | Tachycardia (HR > 120 bpm), bounding pulses, systolic murmur (due to high-output state), possible arrhythmias | In severe anemia, the heart compensates with increased stroke volume; auscultation may reveal a “soft” flow murmur. |
| Respiratory | Rapid panting, increased respiratory rate, possible dyspnea especially in severe cases | Respiratory compensation is less prominent than cardiac; watch for secondary pulmonary edema in massive transfusion. |
| Gastrointestinal | Hematemesis, melena, hematochezia (if hemorrhagic) | Chronic GI bleeding may manifest as occult blood loss -> iron deficiency anemia. |
| Dermatologic | Petechiae, ecchymoses, subcutaneous hemorrhage, especially with coagulopathies or severe IMHA | Visual detection of tiny red spots on the ventral abdomen or skin folds can be a clue. |
| Neurologic | Ataxia, seizures (rare, due to severe hypoxia) | Most dogs maintain neurologic function until profound anemia (< 10 % PCV). |
| Other | Jaundice (icterus) in hemolytic anemia, splenomegaly, lymphadenopathy (immune or infectious etiologies) | Bilirubin elevation causes yellowing of sclerae and mucous membranes. |
Severity Correlation:
- Mild (PCV 30–35 %) – Often subclinical; may be discovered incidentally on CBC.
- Moderate (PCV 20–30 %) – Noticeable lethargy, pale mucous membranes, mild tachycardia.
- Severe (PCV < 20 %) – Marked weakness, collapse, tachypnea, profound pallor, potential shock.
5. Breeds at Higher Risk
Certain canine breeds display a predisposition to specific types of anemia, either because of genetic mutations that affect RBC integrity, immune regulation, or bone‑marrow function. Recognizing breed‑related risk allows for targeted screening and early intervention.
5.1. Immune‑Mediated Hemolytic Anemia (IMHA) – Breed Predisposition
| Breed | Reason for Increased Risk | Notes |
|---|---|---|
| Cocker Spaniel | Historically documented higher incidence of primary IMHA; possible genetic immune dysregulation. | Often present at 2–5 years of age with rapid onset. |
| German Shepherd | Reported higher case numbers in retrospective studies; may be linked to breed‑specific MHC haplotypes. | May have concurrent autoimmune diseases (e.g., hypothyroidism). |
| Doberman Pinscher | Elevated prevalence of IMHA and other autoimmune conditions. | Aggressive disease course; careful monitoring required. |
| Siberian Husky | Documented cases of hereditary spherocytosis, leading to chronic hemolysis. | May present with intermittent anemia from early age. |
| Old English Sheepdog | Higher incidence of hereditary macrocytic anemia (pyruvate kinase deficiency). | Chronic, non‑regenerative anemia; requires lifelong management. |
5.2. Inherited Enzyme Deficiencies (Non‑Regenerative Anemia)
| Breed | Enzyme Defect | Clinical Impact |
|---|---|---|
| Beagle | Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency (rare). | May develop hemolysis after exposure to oxidative drugs. |
| Pomeranian | Pyruvate kinase (PK) deficiency. | Chronic non‑regenerative anemia; often requires transfusion support. |
| Cavalier King Charles Spaniel | Hereditary spherocytosis (rare). | Mild hemolysis, may be misdiagnosed as IMHA. |
5.3. Coagulopathies Leading to Hemorrhagic Anemia
| Breed | Coagulation Disorder | Typical Presentation |
|---|---|---|
| Dachshund | von Willebrand disease (type 1) – most common inherited bleeding disorder in dogs. | Easy bruising, prolonged bleeding after minor trauma; secondary anemia possible. |
| Jack Russell Terrier | Hemophilia A/B (rare). | Severe hemorrhage after trauma or surgery. |
5.4. Parasite‑Related Anemia
While not breed‑specific, certain breeds with short coats (e.g., Greyhounds, Whippets) may acquire higher ectoparasite loads and thus be more susceptible to flea‑ or tick‑borne hemoparasites (e.g., Babesia) that cause hemolytic anemia.
Bottom Line: When evaluating an anemic dog, always ask about breed. A concise breed‑focused differential list helps prioritize testing (e.g., Coombs test for IMHA in Cocker Spaniels, enzyme assays for PK deficiency in Old English Sheepdogs).
6. Age‑Related Considerations
| Life Stage | Predominant Anemia Types | Typical Etiologies |
|---|---|---|
| Puppies (≤ 6 months) | Aplastic (parvoviral infection), hemolytic (congenital enzyme deficiencies), iron deficiency (poor diet, heavy parasite burden). | Canine parvovirus, congenital PK deficiency, severe hookworm infestation. |
| Adult Dogs (1–7 years) | Hemolytic (IMHA, Ehrlichia), hemorrhagic (trauma, GI ulceration), immune‑mediated thrombocytopenia (often concurrent). | Primary IMHA, chronic GI neoplasia, tick‑borne diseases. |
| Senior Dogs (> 7 years) | Anemia of chronic disease (ACD), renal‑associated anemia, cancer‑related hemorrhagic or hemolytic anemia. | Chronic kidney disease, osteosarcoma, lymphoma, heart failure. |
Special Note – Geriatric Dogs: Renal insufficiency impairs erythropoietin (EPO) production, leading to a non‑regenerative, normocytic, normochromic anemia. Monitoring serum creatinine and SDMA, coupled with CBC trends, is essential for early detection.
7. Diagnostic Approach
A systematic work‑up is crucial to differentiate the anemia type, uncover the underlying cause, and guide therapy.
7.1. History & Physical Examination
| Focus Area | Key Questions / Findings |
|---|---|
| Onset | Sudden (hours–days) vs. gradual (weeks–months). |
| Bleeding History | Trauma, surgery, wound, melena, hematuria, nosebleeds. |
| Exposure | Tick/ flea control, travel, diet changes, medications, toxins. |
| Vaccination/Illness | Recent viral infections (parvovirus), respiratory signs (distemper). |
| Breed & Age | As discussed above – may hint toward genetic or age‑related etiologies. |
| Clinical Exam | Mucosal color, CRT, heart/ lung auscultation, abdominal palpation (splenomegaly), lymph node size, skin lesions. |
7.2. Baseline Laboratory Tests
| Test | What It Reveals | Interpretation |
|---|---|---|
| Complete Blood Count (CBC) with Reticulocyte Count | RBC indices (MCV, MCHC), regenerative response, leukogram, platelet count. | Regenerative anemia: Retic > 1.5 % (or absolute > 100 × 10⁹/L). Non‑regenerative: Retic < 1 % with low/normal RBC production. |
| Serum Biochemistry Panel | Organ function (renal, hepatic), electrolytes, glucose, bilirubin, LDH. | Elevated bilirubin → hemolysis; high BUN/creatinine → renal anemia. |
| Urinalysis | Proteinuria, hematuria, specific gravity. | Chronic kidney disease (CKD) support. |
| Coagulation Profile (PT, aPTT, fibrinogen, D‑dimer) | Detects coagulopathies contributing to hemorrhage. | Prolonged PT/aPTT → clotting factor deficiency; low fibrinogen → disseminated intravascular coagulation (DIC). |
| Iron Panel (Serum Iron, TIBC, Ferritin) | Distinguish iron‑deficiency from anemia of chronic disease. | Low serum iron + high TIBC → deficiency; low iron + low TIBC → ACD. |
| Blood Smear Examination | Morphology (spherocytes, schistocytes, Heinz bodies), parasites. | Spherocytes → IMHA; parasites → Babesia, Ehrlichia. |
| Direct Coombs Test (DAT) | Detects antibodies/complement on RBC surface. | Positive DAT → immune‑mediated hemolysis. |
| Bone Marrow Aspirate/Biopsy (if indicated) | Cellular composition, erythroid precursors, infiltrative disease. | Hypocellularity → aplastic; neoplastic infiltration → lymphoma. |
| Serology / PCR for Infectious Agents | Ehrlichia canis, Babesia spp., Mycoplasma haemocanis, Leishmania, Cytauxzoon felis. | Positive PCR = definitive infection, guiding antimicrobial therapy. |
| Abdominal Imaging (Ultrasound, Radiographs) | Detects splenic masses, GI ulceration, neoplasia, organomegaly. | Splenomegaly = possible sequestration or neoplasia. |
| Erythropoietin (EPO) Level (rare) | Evaluates renal EPO production. | Low EPO in CKD supports anemia of chronic disease. |
Diagnostic Algorithm (Simplified):
- CBC + Retic → Regenerative vs. Non‑regenerative.
- If Regenerative:
- Coombs test, blood smear, tick‑borne pathogen PCR, imaging (splenic assessment).
- If Non‑Regenerative:
- Bone marrow aspirate, iron panel, renal profile, infection screen (parvovirus in puppies).
- If Hemorrhagic Signs:
- Coagulation profile, abdominal imaging, stool occult blood, fecal parasite exam.
7.3. Differential Diagnosis Matrix
| Clinical Feature | Likely Category | Key Diagnostic Tests |
|---|---|---|
| Acute onset, pale mucosa, tachycardia, low reticulocyte, no external bleeding | Acute Hemorrhagic (internal) | CBC, PCV trend, abdominal US, fecal occult blood, coagulation profile |
| Jaundice, spherocytes on smear, positive Coombs, high retic | Immune‑Mediated Hemolytic | Coombs, bilirubin, CBC, imaging (splenic, lymph nodes) |
| Chronic mild anemia, low retic, normal iron, high ferritin | Anemia of Chronic Disease | Iron panel, CRP/ESR, underlying chronic disease work‑up |
| Severe anemia, pancytopenia, low retic, bone‑marrow hypocellularity | Aplastic (Myelotoxic) | Bone‑marrow aspirate, drug/toxin history, viral PCR |
8. Treatment Strategies
The therapeutic plan is constructed around three pillars: (1) stabilizing the patient, (2) treating the underlying cause, and (3) supporting erythropoiesis.
8.1. Stabilization & Supportive Care
| Intervention | Indication | Practical Tips |
|---|---|---|
| Fluid Therapy | Hypovolemia secondary to blood loss; maintain perfusion. | Use isotonic crystalloids (Lactated Ringer’s, 0.9% NaCl). Avoid over‑hydration in severe anemia to prevent dilutional worsening. |
| Oxygen Supplementation | Severe tissue hypoxia (PCV < 15 %). | Provide 40–60% FiO₂ via nasal cannula or mask; monitor SpO₂. |
| Blood Transfusion | Life‑threatening anemia (PCV < 15 % or clinical shock). | Fresh, screened donor blood; 10–20 mL/kg over 1–2 h. Cross‑match if possible, especially in previously transfused dogs. Monitor for transfusion reactions (fever, urticaria, hemolysis). |
| Plasma/Clotting Factor Replacement | Coagulopathies (DIC, rodenticide toxicity). | Fresh frozen plasma (FFP) 10–20 mL/kg; Vitamin K₁ (2.5 mg/kg PO q12h) for anticoagulant toxicoses. |
| Analgesia & Sedation | Pain from trauma, splenectomy, or severe anemia. | Use opioid analgesics (e.g., buprenorphine) and short‑acting sedatives (e.g., dexmedetomidine). Avoid NSAIDs if GI ulceration suspected. |
| Nutritional Support | Cachectic or anorexic dogs. | Early enteral feeding; high‑protein, iron‑rich diet (discussed below). |
Transfusion Thresholds (Guideline):
- PCV < 20 % with clinical signs → transfuse.
- PCV < 15 % regardless of signs → transfuse.
- PCV < 10 % – emergency transfusion + ICU monitoring.
8.2. Targeted Therapy Based on Etiology
| Etiology | First‑Line Therapy | Adjunct / Supportive Measures |
|---|---|---|
| Immune‑Mediated Hemolytic Anemia (IMHA) | Immunosuppression: Prednisone 2 mg/kg PO q12h (initial high dose). Add a second agent (azathioprine 2 mg/kg PO q24h, mycophenolate mofetil 10 mg/kg PO q12h, or cyclosporine 5 mg/kg PO q12h) for steroid‑sparing. | • Thromboprophylaxis (e.g., clopidogrel 2 mg/kg PO q24h) – IMHA predisposes to thromboembolism. • Antibiotics only if secondary infection suspected. |
| Hemorrhagic Anemia – Traumatic | Hemostasis: Surgical repair, ligation, topical hemostatics. | • Blood products as needed. • Tranexamic acid (10 mg/kg IV q8h) for adjunctive antifibrinolysis if DIC suspected. |
| Coagulopathy – Rodenticide | Vitamin K₁ (2.5–5 mg/kg PO q12h for 7–10 days). | • Plasma transfusion for immediate factor replacement. • Fresh frozen plasma (FFP) 10–20 mL/kg. |
| Parasite‑Induced Hemolysis (e.g., Babesia, Ehrlichia) | Antiprotozoal / Antibiotic Regimen: • Babesia – Imidocarb dipropionate 5–6 mg/kg SC q72h × 2 doses. • Ehrlichia – Doxycycline 10 mg/kg PO q12h for 4 weeks. |
• Supportive care: transfusion, fluid therapy. |
| Aplastic Anemia (Drug‑Induced) | Discontinue offending agent. | • Immunosuppressive therapy (if immune‑mediated aplasia suspected). • EPO therapy (recombinant human EPO 100 IU/kg SC q48h) may stimulate erythropoiesis in select cases. |
| Anemia of Chronic Disease (renal insufficiency) | Treat underlying disease (e.g., ACE inhibitors for CKD). | • Recombinant EPO as above. • Iron supplementation only if iron deficiency co‑exists (avoid in pure ACD). |
| Iron‑Deficiency Anemia (Parasite/ Diet) | Oral iron (e.g., ferrous sulfate 3 mg/kg PO q12h). | • Deworming (e.g., fenbendazole 50 mg/kg PO q24h × 3 days). • Dietary modification (high‑bioavailable iron). |
8.3. Adjunct Therapies
- Recombinant Erythropoietin (rEPO): Useful in chronic renal anemia or refractory non‑regenerative anemia. Start at 100 IU/kg SC q48h; monitor PCV weekly, adjust dose to avoid polycythemia.
- Iron Supplementation: Oral (ferrous sulfate, gluconate) or parenteral (iron dextran) if iron deficiency confirmed. Watch for GI upset and oxidative stress; give with food.
- Vitamin B12 (Cobalamin) & Folate: Deficiencies can impair DNA synthesis in marrow. Give cyanocobalamin 250 µg SC q2wks for 6 weeks, then q4–6 weeks. Folate 0.1 mg PO q12h for 2–4 weeks.
- Antioxidants: N‑acetylcysteine (NAC) 10–20 mg/kg PO q12h may reduce oxidative hemolysis in G6PD‑deficient dogs or after toxin exposure.
9. Prognosis & Potential Complications
| Condition | Expected Prognosis (with appropriate treatment) | Common Complications |
|---|---|---|
| Primary IMHA | 60–80 % survival with aggressive immunosuppression; relapse rates 20–30 %. | Thromboembolism (pulmonary emboli), opportunistic infections, steroid‑induced Cushing’s, pancreatitis. |
| Secondary IMHA (infectious) | Variable; depends on control of underlying infection. | Relapse if infection persists; drug resistance. |
| Acute Hemorrhagic Anemia (trauma) | Good to excellent if hemorrhage controlled and transfusion given promptly. | DIC, hypovolemic shock, organ failure. |
| Aplastic Anemia | Guarded to poor; survival < 30 % unless reversible cause identified. | Persistent pancytopenia, severe infections, bleeding. |
| Chronic Kidney Disease–Related Anemia | Stable with EPO and diet; may require lifelong treatment. | Progression of CKD, hypertension. |
| Iron‑Deficiency Anemia | Excellent once parasites cleared and diet corrected. | Recurrence if deworming lapses. |
| Inherited Enzyme Deficiencies | Lifelong management; generally good quality of life with transfusion support. | Frequent transfusion reactions, iron overload (secondary hemosiderosis). |
Key Prognostic Indicators
- Regenerative response: Presence of reticulocytosis predicts better outcomes.
- Severity at presentation: PCV < 10 % correlates with higher mortality.
- Co‑morbidities: Concurrent renal, hepatic, or cardiac disease worsens prognosis.
- Speed of diagnosis: Early identification (e.g., within 24 h for IMHA) improves survival.
10. Prevention Strategies
- Vaccination & Parasite Control
- Core vaccines (e.g., canine distemper, parvovirus) reduce viral causes of aplastic anemia.
- Monthly heartworm preventatives (ivermectin, milbemycin) and regular fecal exams for intestinal parasites decrease blood loss and hemoparasite exposure.
- Genetic Screening & Breeding Practices
- DNA testing for known immune‑mediated predispositions (e.g., DLA haplotypes linked to IMHA) in high‑risk breeds.
- Avoid breeding dogs with confirmed hereditary anemia (e.g., PK deficiency).
- Toxin Avoidance
- Keep rodenticides, heavy metals, and certain plants (e.g., onion, garlic) out of reach.
- Use veterinarian‑approved flea & tick products (avoid organophosphate sprays that can cause hemolysis).
- Nutrition & Iron Bioavailability
- Provide balanced commercial diets formulated for the life stage; supplement with iron only under veterinary guidance.
- For working or high‑energy breeds, a diet with high‑quality animal protein ensures adequate heme‑iron.
- Regular Health Checks
- Annual CBCs for senior dogs and at least bi‑annual CBCs for breeds predisposed to IMHA.
- Early detection of mild anemia allows prompt investigation before catastrophic decompensation.
11. Dietary & Nutritional Recommendations
| Nutrient | Role in Anemia Management | Practical Sources |
|---|---|---|
| Protein (High‑Biological‑Value) | Supplies amino acids for hemoglobin synthesis and marrow cellularity. | Chicken, turkey, beef, fish; commercial diets ≥ 30 % protein for adult dogs. |
| Heme Iron (Fe²⁺ from animal sources) | Most bioavailable form (~25 % absorption). | Liver (beef or chicken), red meat, fish. |
| Non‑Heme Iron (Fe³⁺ from plant sources) | Lower absorption; enhanced by vitamin C. | Spinach, lentils (cooked), beans. |
| Vitamin C | Increases non‑heme iron absorption; antioxidant that protects RBC membranes. | Citrus fruits (limited, as high acidity may cause GI upset), bell peppers, strawberries. |
| Vitamin B12 (Cobalamin) & Folate | Essential for DNA synthesis in erythroid precursors. | Liver, egg yolk, fortified kibble. |
| Copper | Cofactor for ceruloplasmin, needed for iron metabolism. | Beef liver, organ meats, whole grains (moderate). |
| Zinc | Supports immune function; deficiency can impair erythropoiesis. | Meat, dairy, pumpkin seeds. |
| Omega‑3 Fatty Acids (EPA/DHA) | Anti‑inflammatory; may reduce immune‑mediated hemolysis. | Salmon oil, fish oil supplements (EPA ≈ EPA 1,000 mg, DHA ≈ 500 mg per day for a 20 kg dog). |
| Antioxidants (Vitamin E, Selenium) | Protect RBC membranes from oxidative damage. | Wheat germ oil (Vitamin E), Brazil nuts (Selenium, feed in moderation). |
Feeding Guidelines
- Adult Dogs (20–30 kg): 2–3 % of body weight in dry kibble or equivalent wet food per day, divided into two meals.
- Puppies & Growing Dogs: 3–4 % of body weight; ensure calcium‑phosphorus ratio of 1.2:1 to 1.4:1.
- Senior Dogs: Energy requirements decline (~1 % BW), but protein should remain high (≥ 30 % of calories) to preserve lean mass.
Supplementation Cautions
- Iron Overload: Chronic transfusions can cause hemosiderosis; monitor serum ferritin. Avoid routine iron supplementation unless deficiency is confirmed.
- Vitamin K₁: Only give under veterinary direction; excess can cause hypercoagulability.
- EPO: Use only when indicated; monitor for hypertension and thrombosis.
12. Zoonotic Considerations
While most canine anemia etiologies are not zoonotic, a few infectious agents can affect humans, especially immunocompromised individuals.
| Zoonotic Agent | Transmission Mode | Human Disease | Prevention |
|---|---|---|---|
| Babesia canis (rare strains) | Tick bite (Ixodes spp.) | Babesiosis (febrile hemolytic disease) | Tick control on dogs and owners; avoid direct contact with tick‑infested dogs. |
| Ehrlichia canis (occasionally) | Tick bite (Rhipicephalus sanguineus) | Human ehrlichiosis (flu‑like illness) | Same tick precautions; hand hygiene after handling dogs. |
| Leishmania infantum (Mediterranean & South America) | Sand‑fly bite (Phlebotomus spp.) | Cutaneous & visceral leishmaniasis | Use insecticidal collars, indoor housing, avoid sand‑fly habitats. |
| Rickettsia rickettsii (Rocky Mountain spotted fever) | Tick bite (Dermacentor spp.) – dogs can be sentinels | Severe febrile illness in humans | Vector control; prompt tick removal. |
| Rodenticide exposure (e.g., warfarin) | Accidental ingestion of contaminated dog feces | Coagulopathy in humans | Keep anticoagulant rodenticides secured; wear gloves when cleaning. |
Veterinary Practice Safety
- Wear gloves when drawing blood from anemic dogs, especially if hemolytic disease is suspected.
- Perform proper hand hygiene after handling animals with known zoonotic infections.
- Educate owners about tick prevention for both pets and family members.
13. Summary Checklist for Clinicians
| Step | Action |
|---|---|
| 1. History | Ascertain onset, bleeding, exposure, breed, age. |
| 2. Physical Exam | Look for pallor, jaundice, splenomegaly, petechiae. |
| 3. CBC + Retic | Determine regenerative vs. non‑regenerative. |
| 4. Blood Smear | Morphology, parasites, spherocytes. |
| 5. Coombs Test | Screen for IMHA. |
| 6. Biochem & Urinalysis | Evaluate organ function, bilirubin, renal status. |
| 7. Imaging | Ultrasound for internal bleeding, splenic lesions. |
| 8. Targeted Tests | PCR/serology for tick‑borne agents; iron panel; coag labs. |
| 9. Bone Marrow (if non‑regenerative & cause unclear). | |
| 10. Initiate Support | Fluids, O₂, transfusion as needed. |
| 11. Specific Therapy | Immunosuppression, antibiotics, antiparasitics, vitamin K₁, EPO, iron. |
| 12. Monitor | PCV every 12–24 h initially, then daily; watch for transfusion reactions, thromboembolism. |
| 13. Client Education | Discuss prognosis, home care, diet, preventive measures. |
#DogAnemia, #CanineHealth, #PetWellness, #VeterinaryMedicine, #IMHA, #HemolyticAnemia, #DogNutrition, #PetParents, #DogCareTips, #SeniorDogHealth, #PuppyHealth, #DogBreeds, #BloodDisorders, #VeterinaryEducation, #DogBloodWork, #PetPrevention, #TickBorneDiseases, #DogDiet, #HealthyPup, #DogLovers, #PetSafety, #ZoonoticRisks, #VetLife, #DogOwners, #DogLife, #AnimalScience, #DogWellbeing, #PetHealthAwareness, #CanineBloodTransfusion, #DogMedicalGuide
Add comment